Danicopan

Danicopan
Danicopan_structure.svg
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

Danicopan is an investigational oral medication that acts as a complement factor D inhibitor. It is primarily being studied for its potential use in treating paroxysmal nocturnal hemoglobinuria (PNH), a rare and life-threatening blood disorder.

Mechanism of Action

Danicopan works by inhibiting the activity of complement factor D, a serine protease that plays a crucial role in the activation of the alternative complement pathway. By blocking this pathway, Danicopan prevents the destruction of red blood cells, which is a hallmark of PNH. This mechanism helps to reduce hemolysis and improve the clinical symptoms associated with the disease.

Clinical Development

Danicopan is currently undergoing clinical trials to evaluate its safety and efficacy in patients with PNH. Early studies have shown promising results, with significant reductions in hemolysis markers and improvements in hemoglobin levels. The drug is being developed by Alexion Pharmaceuticals, a company known for its focus on rare diseases.

Potential Benefits

The use of Danicopan in PNH patients could offer several benefits, including:

• Reduction in the need for blood transfusions
• Improvement in quality of life
• Decrease in the risk of thrombotic events

Side Effects

As with any medication, Danicopan may cause side effects. Commonly reported adverse effects include:

• Headache
• Nausea
• Fatigue

Patients receiving Danicopan should be monitored for any signs of infection, as complement inhibition can increase susceptibility to certain infections.

Related pages

• Paroxysmal nocturnal hemoglobinuria
• Complement system
• Alexion Pharmaceuticals